The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells

BACKGROUND: New drugs for adrenocortical carcinoma (ACC) are needed because most patients undergo rapid disease progression despite surgery and adjuvant therapy with mitotane. In this study, we aimed to investigate the in vitro effects of different chemotherapy drugs, alone or combined with mitotane...

Descripción completa

Detalles Bibliográficos
Autores principales: Silveira, Elaine, Cavalcante, Isadora Pontes, Kremer, Jean Lucas, de Mendonça, Pedro Omori Ribeiro, Lotfi, Claudimara Ferini Pacicco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831608/
https://www.ncbi.nlm.nih.gov/pubmed/29507530
http://dx.doi.org/10.1186/s12935-018-0527-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831608/
https://www.ncbi.nlm.nih.gov/pubmed/29507530
http://dx.doi.org/10.1186/s12935-018-0527-x

Ejemplares similares